L'intérêt à découvert pour Holley donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Holley. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Holley (NYSE:HLLY) Stock, Rapport sur les intérêts à découvert

HOLLEY INC

Holley

Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.

Holley Inc

Warren Buffett is worth over $145 billion, runs one of the largest conglomerates in the world, and <a href="https://www.benzinga.com/personal-finance/24/09/40971688/warren-buffett-owns-28b-in-coca-cola-stock-and-drinks-5-cans-a-day-i-dont-think-the-prostate-can">drinks five Cherry Cokes a day</a> — but, according to his daughter, he's never touched a sip of water. Ever.
And while it's well known that Buffett has never had an alcoholic drink in his life, what's less expected is that this 94-year-old billionaire has no problem investing in both alcohol and water companies — despite steering clear of both on a personal level.
"I've never in my life — and I'm not kidding — seen the man drink a sip of water," his daughter <a href="https://youtu.be/w-eX4sZi-Zs?si=Nc59LbFeXLIcX5Wm">Susie Buffett said in the 2009 documentary</a>, "The World&#8217;s Greatest Money Maker: Warren Buffett."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Nearly a decade later, in the <a href="https://youtu.be/i45_qjgFmxg?si=O1WagnxCDyPF9_cp">2017 HBO documentary "Becoming Warren Buffett</a>," she doubled down: "He doesn't drink water. He doesn't do anything he's supposed to do. And he's healthy."
When asked about alcohol in various interviews, Buffett has been consistent: he's never had a drink. As <a href="https://www.independent.co.uk/news/business/analysis-and-features/warren-buffet-the-secret-of-the-billionaire-s-success-1622649.html">The UK Independent</a> noted, Buffett has never smoked or consumed alcohol and said he avoids both to protect his health.
During a Berkshire Hathaway annual shareholder meeting years ago, he once explained the logic using one of his signature metaphors:
Imagine you're 16 years old and a genie gives you any car you want, he told students — but warns it's the only car you'll ever own.
"Now, if you're smart, you'll take care of that car," Buffett said. "Well, you only get one body and one mind — and it has to last a lifetime."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
That mindset might help explain how Buffett's made it to 94 with a sugar-heavy diet and a zero-water, zero-alcohol policy — but when it comes to his investments, it's a different story entirely.
In late 2024, Buffett's Berkshire Hathaway invested $1.24 billion in Constellation Brands, the parent company of Corona beer, Modelo, and Robert Mondavi wines. By early this year, the position more than doubled, making it one of Berkshire's biggest bets in the consumer goods space. The company now owns more than 6.6% of Constellation.
Berkshire has also long held a position in the water industry. Through its Marmon Group, Berkshire owns EcoWater Systems, which produces residential and commercial water treatment products. Berkshire was also the second-largest shareholder of Nalco, a major water-treatment chemical firm, before it merged into Ecolab.
Fellow billionaire Bill Gates <a href="https://www.benzinga.com/news/education/25/07/46265960/elon-musk-and-bill-gates-share-a-surprising-view-on-alcohol#">has a similar stance.</a> While he's said he's "not a big beer drinker," he's still invested heavily in the alcohol industry.
See Also: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
In a <a href="https://www.reddit.com/r/IAmA/comments/80ow6w/im_bill_gates_cochair_of_the_bill_melinda_gates/">2018 Reddit AMA</a>, Gates admitted:
"I am not a big beer drinker. When I end up at something like a baseball game I'll drink light beer to get with the vibe."&nbsp;
Despite that, in February 2023, Gates' trust and personal accounts co-purchased a <a href="https://www.bloomberg.com/news/articles/2023-02-22/billionaire-gates-buys-stake-in-heineken-s-controlling-holder">$902 million stake</a> in Heineken Holding—the parent company of Heineken beer.&nbsp;
So why the disconnect between personal lifestyle and portfolio strategy?
Well, as Buffett himself once said in a <a href="https://www.cnbc.com/2018/02/26/buffett-says-out-of-the-three-ways-to-go-broke-liquor-ladies-and-leverage-leverage-is-the-worst.html">2018 CNBC interview</a>:
"My partner Charlie says there are only three ways a smart person can go broke: liquor, ladies, and leverage."
Buffett's avoided all three in his personal life. But in the markets? He knows opportunity when he sees it — even if he wouldn't drink to it
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Personal Finance

Warren Buffett Has Never Had a Drop of Alcohol — Or Water, According To His Daughter, But He's Invested Billions in Both Industries

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) has outperformed the market over the past 5 years by 2.31% on an annualized basis producing an average annual return of 16.75%. Currently, Phillips 66 has a market capitalization of $54.76 billion. 
Buying $100 In PSX: If an investor had bought $100 of PSX stock 5 years ago, it would be worth $222.98 today based on a price of $134.39 for PSX at the time of writing.
<h3>Phillips 66's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752188454_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Shares of Brazilian aircraft manufacturer Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) dropped on Thursday after President Donald Trump announced plans to impose a 50% tariff on all<a href="https://www.benzinga.com/news/25/07/46350703/airline-stocks-surge-trump-tariffs-hit-brazil"> imports from Brazil. </a>
As the world's third-largest aircraft maker, Embraer relies heavily on the U.S. market for both its executive jets and regional airliners, making it particularly vulnerable to the proposed trade measures.
Read Next:<a href="https://www.benzinga.com/news/health-care/25/07/46355532/unitedhealth-hits-reset-new-head-of-medicaid-appointed-as-ceo-reshapes-team?utm_source=articleShare"> UnitedHealth Hits Reset: New Head Of Medicaid Appointed As CEO Reshapes Team</a>&nbsp;
What To Know: In response, Embraer stated it is assessing how the tariffs might affect its business and plans to provide more details during its second-quarter earnings call on Aug. 5. The company also mentioned it is working with authorities to try to reinstate a zero import tax rate for the aerospace sector, according to Reuters. 
According to analysts at Itau BBA, 60% of Embraer's revenue comes from North America, and about three-quarters of that could be subject to the new tariffs.&nbsp;
They estimate the tariffs could reduce Embraer's earnings before interest and taxes (EBIT) by $150 million between August and December, Reuters reported.&nbsp;
Why It Matters: Aircraft are among the top U.S. imports from Brazil, alongside products like oil, steel, coffee and orange juice.&nbsp;
Embraer's E1 jets are a mainstay of U.S. regional airlines, with SkyWest recently ordering 60 E175 aircraft. The company also enjoys strong demand for its business jets in the U.S.
In February, Embraer Executive Jets entered into a <a href="https://www.benzinga.com/25/02/43496469/aircraft-manufacturer-embraer-bags-7b-order-stocks-surge">major purchase agreement </a>with Flexjet valued at up to $7 billion. The deal included a firm order for 182 aircraft, along with 30 additional options, and features an upgraded package of services and support.&nbsp;
Despite the recent drop, Embraer's shares are still up more than 30% for the year, following a 150% surge last year. Earlier this month, the stock reached a record high, driven by strong global demand for its aircraft.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

Politics

Travel

Global

Movers

General

Embraer-Empresa Brasileira De Aeronautica

Trump's 50% Tariffs Send This Jet Maker Into A Tailspin

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) delivered a jolt of optimism to Wall Street Thursday, as its stock surged 12% after the company reported better-than-expected second-quarter earnings and reinstated its <a href="https://www.benzinga.com/markets/earnings/25/07/46341383/delta-air-lines-ceo-confident-in-stronger-2025-as-demand-holds-steady">full-year profit outlook.</a>&nbsp;
The rally led airline stocks higher across the board with investor confidence returning to the sector.&nbsp;
The Details: Delta reported adjusted earnings of $2.10 per share, topping expectations of $2.05.&nbsp;
Passenger revenue surged 26% to $13.88 billion and operating revenue for the quarter was $16.65 billion, above the <a href="https://www.benzinga.com/earnings">consensus estimate</a> of $16.18 billion.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/health-care/25/07/46355532/unitedhealth-hits-reset-new-head-of-medicaid-appointed-as-ceo-reshapes-team?utm_source=articleShare"> UnitedHealth Hits Reset: New Head Of Medicaid Appointed As CEO Reshapes Team</a>&nbsp;
CEO Ed Bastian told analysts on a conference call Thursday that Delta's premium and loyalty segments continue to show resilience and growth and helped to offset some lingering softness in the main cabin.&nbsp;
"Our core consumer is in good shape and continues to prioritize travel and affinity for Delta's brand has never been stronger," Bastian said.&nbsp;
"This is evidenced by the sustained strength of our premium products and our industry-leading co-brand card with consumer spend growth on the Delta American Express card up double digits in the first half of the year," the CEO added.  
Bastian also said he expects the passage of Trump's tax and spending bill and progress on trade negotiations to restore some economic certainty and stability.&nbsp;
"We expect both consumer and corporate confidence to improve in the second half of the year, creating the environment for travel demand to accelerate," Bastian said on Delta's earnings call.&nbsp;
What Else: Other airline stocks moved higher in sympathy with Delta as investor confidence in the sector grew following the stronger-than-expected earnings report.&nbsp;
Shares of United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) ended Thursday's session 14.3% higher and American Airlines Group Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/AAL#NASDAQ">A AL</a>) stock closed 12.7% higher at $12.94, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
DAL Price Action: Delta Air Lines shares ended Thursday&#8217;s session up 12% at $56.79. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

Earnings

Management

Delta Air Lines Weathers The Storm: CEO Expects 'Demand To Accelerate' To Wrap 2025

Trading in Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is quiet on Thursday. The stock has <a href="https://www.benzinga.com/markets/tech/25/07/46337313/apple-needs-product-focused-ceo-say-analysts-as-tim-cook-faces-heat-over-ai-failures-and-innovation-slump">not participated</a> in the recent broad market rally. While NVIDIA Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) have soared to all-time highs, Apple has lagged.
But now there&#8217;s a chance Apple could be about to put some downward pressure on the market. This is why it is the Stock of the Day.
Despite its lackluster performance, Apple is still the third-largest stock in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>): Nvidia is 14.88%, Microsoft makes up 14.02%, and Apple is 11.81%. This means that the direction of Apple's stock can still have a significant impact on others within the technology sector.
As you can see on the chart, Apple once again found resistance around the $213 level for the third time since May. The last two times this happened, a meaningful sell-off followed.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10141114/Apple.july2025one-1024x571.png" alt="" class="wp-image-980577" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10141114/Apple.july2025one-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10141114/Apple.july2025one-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10141114/Apple.july2025one-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10141114/Apple.july2025one.png 1474w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46342321/nvidia-microsoft-apple-smash-10-trillion-is-this-peak-tech">Nvidia, Microsoft, Apple Smash $10 Trillion—Is This Peak Tech?</a>
Stocks frequently reverse and sell off after hitting a resistance level.
Resistance is a large group of traders and investors who wish to sell shares at, or close to, the same level. There are enough or more than enough sell orders to fill all of the buy orders. This is why rallies end, or at least pause, when this is reached.
Stocks can sell off of resistance when some traders and investors, who wish to sell, become anxious. They know the buyers will go to whoever is willing to sell them shares at the lowest price.
These anxious sellers worry that another seller will undercut them. As a result, they reduce their offer prices. Other anxious sellers see this and do the same thing. It can turn into a snowball effect that forces the price lower.
There is a good chance that Apple is about to sell off of this resistance for a third time. This could put downward pressure on the technology sector. And that could put downward pressure on the broader market.
Read Next: • <a href="https://www.benzinga.com/news/25/07/46350703/airline-stocks-surge-trump-tariffs-hit-brazil">Airline Stocks Take Off, Trump Hits Brazilian ETF: What&#8217;s Moving Markets Thursday?</a>
Photo: Shutterstock

Technicals

Tech

AAPL

MSFT

NVDA

Stock Of The Day: Will Apple Bring Tech Sector Down?

Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) has outperformed the market over the past 10 years by 6.19% on an annualized basis producing an average annual return of 17.69%. Currently, Paylocity Holding has a market capitalization of $10.22 billion. 
Buying $1000 In PCTY: If an investor had bought $1000 of PCTY stock 10 years ago, it would be worth $5,159.66 today based on a price of $182.91 for PCTY at the time of writing.
<h3>Paylocity Holding's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752187521_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCTY

Here's How Much $1000 Invested In Paylocity Holding 10 Years Ago Would Be Worth Today

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 12.01% on an annualized basis producing an average annual return of 26.44%. Currently, East West Bancorp has a market capitalization of $14.90 billion. 
Buying $100 In EWBC: If an investor had bought $100 of EWBC stock 5 years ago, it would be worth $313.72 today based on a price of $108.14 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752186613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

$100 Invested In East West Bancorp 5 Years Ago Would Be Worth This Much Today

Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) has outperformed the market over the past 5 years by 42.65% on an annualized basis producing an average annual return of 57.09%. Currently, Targa Resources has a market capitalization of $37.04 billion. 
Buying $1000 In TRGP: If an investor had bought $1000 of TRGP stock 5 years ago, it would be worth $9,984.80 today based on a price of $170.74 for TRGP at the time of writing.
<h3>Targa Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752185712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRGP

Here's How Much You Would Have Made Owning Targa Resources Stock In The Last 5 Years

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and lowers the price target from $30 to $26.

Price Target

Analyst Ratings

NRIX

UBS Maintains Buy on Nurix Therapeutics, Lowers Price Target to $26

UBS analyst Robin Farley maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Neutral and lowers the price target from $160 to $149.

UBS Maintains Neutral on Choice Hotels Intl, Lowers Price Target to $149

UBS analyst Kenneth Fong maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $58 to $50.

UBS Maintains Buy on JD.com, Lowers Price Target to $50

Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has high hopes for its "Superman" reboot film, set for theaters this weekend. The film has been<a href="https://www.benzinga.com/general/entertainment/22/12/30116813/its-a-bird-its-a-plane-its-a-superhero-movie-franchise-rebrand-that-could-help-this-stock" target="_blank" rel="noopener"> years in the making</a> and is a potential relaunch of the DC Comics movie universe, but one former Superman actor is crying foul over the plot.
What Happened: Director James Gunn was announced <a href="https://www.benzinga.com/general/entertainment/23/02/30678077/its-a-bird-its-a-plane-its-dc-comics-new-movies-tv-shows-announced">as the man behind </a>the "Superman" reboot years ago and the man tasked with helping turn DC Comics&#8217; film and TV strategy around.
Gunn's new superhero film is being called "woke" by actor Dean Cain, who famously played Superman in the TV show "Lois &amp; Clark" from 1993 to 1997.
"How woke is Hollywood going to make this character?" Cain told <a href="https://www.tmz.com/2025/07/09/superman-dean-cain-immigrant-controversy/">TMZ</a>. "How much is Disney going to change their Snow White? Why are they going to change their characters (to) exist for the times?"
Cain's comments, reported by <a href="https://variety.com/2025/film/news/dean-cain-superman-woke-maga-backlash-immigrant-1236451732/">Variety</a>, come after Gunn shared that Superman is an "immigrant that came from other places and populated the country" in the film, adding that the film represents "the story of America."
"For Superman, it was ‘truth, justice, and the American way.' Well, they dropped that…They came up with ‘truth, justice, and a better tomorrow.' Changing beloved characters I don't think is a great idea. If you want to create a new character go ahead and do that," Cain also said.
Cain went on to criticize America's immigration policies.
"There have to be limits, because we can't have everybody in the United States. We can't have everybody, society will fail. So there have to be limits."
Cain's not the only one speaking out about the film's plot line, in which Superman is portrayed as an immigrant.
Fox News recently referred to the film as "SuperWoke."
Fox News contributor Kellyanne Conway criticized the film&#8217;s plot line.
"We don't go to the movie theater to be lectured to and to have somebody throw their ideology onto us," Conway said.
Gunn has brushed off the criticism ahead of the film's July 11 release, telling Variety he doesn't have "anything to say to anybody" spreading hate about his film.
"I think this is a movie about kindness and I think that's something everyone can relate to," Gunn said.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a>
Why It's Important: The potential boycott of the film by Republicans and public criticism from a former Superman actor could end up hurting the film's box office.
"I think it was a mistake by James Gunn to say it's an immigrant thing, and I think it's going to hurt the numbers on the movie," Cain said.
The film is expected to gross $120 million to $130 million domestically in its opening weekend, according to <a href="https://variety.com/2025/film/box-office/superman-box-office-opening-weekend-projection-1236448799/">Variety</a>. The studio has been more conservative with estimates saying it expects $100 million to $110 million.
Early positive reactions from critics and fans could also take the film past $140 million domestically, according to the report. On Rotten Tomatoes, the film has an 82% rating from critics and a 96% rating from early viewers of the film.
The "Superman" film had a $225 million production budget and could also gross $100 million in international markets in its opening weekend.
The last standalone Superman film was "Man of Steel" in 2013. That film <a href="https://www.boxofficemojo.com/franchise/fr340233989/?ref_=bo_frs_table_6">grossed </a>$291.0 million domestically with an opening domestic weekend total of $116.6 million. The last film featuring Superman was Justice League, released in 2017, which grossed $229.0 million domestically and opened with $93.8 million.
The best recent Superman film performance is 2016's "Batman vs. Superman: Dawn of Justice." That film grossed $330.4 million domestically and opened to a $166.0 million domestic total.
WBD Price Action: Warner Bros. Discovery shares were up 1.4% to $11.65 on Thursday versus a 52-week trading range of $6.64 to $12.76. Warner Bros. stock is up 9.3% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45320845/warner-bros-stock-jumps-on-streaming-growth-the-last-of-us-minecraft-movie-could-mean-even-bigger-gains-in-q2">Warner Bros. Stock Jumps On Streaming Growth: &#8216;The Last Of Us,&#8217; &#8216;Minecraft Movie&#8217; Could Mean Even Bigger Gains In Q2</a></li>
</ul>
Photo: John B Hewitt / Shutterstock.com

Entertainment

Superman An Immigrant? Superhero Actor Says Warner Bros. Film Is Woke, Issues Box Office Warning

UBS analyst Douglas Harter maintains Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Buy and lowers the price target from $13 to $12.

UBS Maintains Buy on Two Harbors Inv, Lowers Price Target to $12

UBS analyst Brock Vandervliet maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Neutral and raises the price target from $8.5 to $9.5.

AGNC

UBS Maintains Neutral on AGNC Investment, Raises Price Target to $9.5

UBS analyst Doug Harter maintains Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Neutral and raises the price target from $10 to $10.5.

AOMR

UBS Maintains Neutral on Angel Oak Mortgage REIT, Raises Price Target to $10.5

UBS analyst Douglas Harter maintains ARMOUR Residential REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARR#NYSE">ARR</a>) with a Neutral and raises the price target from $14 to $16.

UBS Maintains Neutral on ARMOUR Residential REIT, Raises Price Target to $16

UBS analyst Douglas Harter maintains Chimera Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>) with a Buy and raises the price target from $15 to $16.

UBS Maintains Buy on Chimera Investment, Raises Price Target to $16

Ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.75, a high estimate of $65.00, and a low estimate of $64.00. This current average has decreased by 10.07% from the previous average price target of $72.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184856_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Ultragenyx Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Sami Corwin</td>
<td>William Blair</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Ultragenyx Pharmaceutical</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Ultragenyx Pharmaceutical's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.99% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -108.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -75.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.73%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio stands notably higher than the industry average, reaching 0.27. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RARE

Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views

Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $2.69, with a high estimate of $3.25 and a low estimate of $2.25. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184847_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Granite Point Mortgage among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$2.75</td>
<td>$2.25</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.25</td>
<td>$2.50</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$2.25</td>
<td>$2.50</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$3.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Granite Point Mortgage. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Granite Point Mortgage compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Granite Point Mortgage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Granite Point Mortgage's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GPMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Granite Point Mortgage analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Granite Point Mortgage</h2>
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
<h3>Understanding the Numbers: Granite Point Mortgage's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Granite Point Mortgage's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -17.79%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Granite Point Mortgage's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -105.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Granite Point Mortgage's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.74%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Granite Point Mortgage's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.42.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GPMT

Expert Outlook: Granite Point Mortgage Through The Eyes Of 4 Analysts

Analysts' ratings for Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $181.67, along with a high estimate of $200.00 and a low estimate of $152.00. This upward trend is apparent, with the current average reflecting a 6.45% increase from the previous average price target of $170.67.
<img src="https://www.benzinga.com/files/images/story/2025/1752184839_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Ares Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$189.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$197.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ares Management. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ares Management compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ares Management's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ares Management's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Management analyst ratings.</a>
<h2>Delving into Ares Management's Background</h2>
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate &amp; infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, &amp; credit.
<h3>Ares Management: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Ares Management's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 53.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Ares Management's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ares Management's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.86%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.08%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ares Management's debt-to-equity ratio surpasses industry norms, standing at 4.46. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Ares Management Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Legal

Press Releases

Alert to Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra LifeSciences Holdings Corporation (NASDAQ: IART); Outset Medical, Inc. (NASDAQ: OM); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Is Investigating Claims on Your Behalf

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Comments

Holley

Intérêt court

Holley (NYSE:HLLY) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL